

10 July 2009

Proposal for Apotex risperidone and topiramate

PHARMAC is seeking feedback on a proposal to fund a new brand of risperidone tablets and oral liquid (Apo-Risperidone) and topiramate tablets (Apo-Topiramate), through a provisional agreement with Apotex NZ Limited. Key aspects of the proposal are detailed below.

From 1 December 2009, Apo-Risperidone and Apo-Topiramate would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule at the following prices and subsidies (ex-manufacturer, excluding GST).

Pharmaceutical	Brand	Form and Strength	Pack Size	Proposed price and subsidy
Risperidone	Apo-Risperidone	Tab 0.5 mg	60	\$7.80
Risperidone	Apo-Risperidone	Tab 1 mg	60	\$15.39
Risperidone	Apo-Risperidone	Tab 2 mg	60	\$30.77
Risperidone	Apo-Risperidone	Tab 3 mg	60	\$46.16
Risperidone	Apo-Risperidone	Tab 4 mg	60	\$61.53
Risperidone	Apo-Risperidone	Oral liquid 1 mg per ml	100 ml	\$61.16
Topiramate	Apo-Topiramate	Tab 25 mg	60	\$13.02
Topiramate	Apo-Topiramate	Tab 50 mg	60	\$22.13
Topiramate	Apo-Topiramate	Tab 100 mg	60	\$37.63
Topiramate	Apo-Topiramate	Tab 200 mg	60	\$64.93

Subject to Medsafe registration, Apo-Risperidone oral liquid 1 mg per ml in a 30 ml pack size would also be listed at a price and subsidy of \$18.35 (ex-manufacturer, excluding GST), potentially instead of the 100 ml pack size, depending on the timing of registration.

Apo-Risperidone and Apo-Topiramate would have protection from delisting and subsidy reduction until 1 July 2012.

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **4 pm on Friday 24 July 2009** to:

Geraldine MacGibbon
 Therapeutic Group Manager
 PHARMAC
 PO Box 10 254
 Wellington 6143

Email: geraldine.macgibbon@pharmac.govt.nz

Fax: (04) 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.